Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11942098 | 0.83 | HSPB1 (0.36) | HSPB1FFAR4MAPTALDH1A1MEN1 | |
| SCHEMBL5261995 | 0.82 | HSPB1 (0.56) | HSPB1MAPTALDH1A1PIN1MAPK1 | |
| SCHEMBL11951790 | 0.80 | FFAR4 (0.42) | FFAR4MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL23242547 | 0.78 | TDP1 (0.45) | FFAR4MAPTALDH1A1PKMTDP1 | |
| SCHEMBL1956277 | 0.76 | FFAR4 (0.44) | HSPB1FFAR4MAPTALDH1A1MEN1 | |
| SCHEMBL2445073 | 0.75 | PIN1 (0.47) | HSPB1PIN1 | |
| SCHEMBL31371566 | 0.75 | HSPB1 (0.52) | HSPB1MAPTALDH1A1PDGFRBFGFR1 | |
| SCHEMBL539834 | 0.75 | TDP1 (0.47) | MAPTALDH1A1PDGFRBFGFR1PDGFRA | |
| SCHEMBL14621420 | 0.74 | HSPB1 (0.48) | HSPB1MAPTMEN1KMT2APIN1 | |
| SCHEMBL31176892 | 0.74 | L3MBTL1 (0.51) | MAPTALDH1A1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20170158666-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158666-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20150329541-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329541-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2944638-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Bahamas Limited (BS) | 2015-11-18 | — | — | EP | disclosed |
| US-9174982-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174982-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2576546-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE BAHAMAS LTD (BS) | 2015-07-22 | — | — | EP | disclosed |
| EP-2435432-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE BAHAMAS LTD (BS) | 2015-06-24 | — | — | EP | disclosed |
| US-20130267534-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-8546399-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546399-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BRUNCKO MILAN (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HSPB1 84/4885FFAR4 3854/4885MAPT 3890/4885 |
| US-20150329541-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HSPB1 84/4885FFAR4 3854/4885MAPT 3890/4885 |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HSPB1 84/4885FFAR4 3854/4885MAPT 3890/4885 |
| US-20170158666-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HSPB1 84/4885FFAR4 3854/4885MAPT 3890/4885 |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HSPB1 89/4885FFAR4 3784/4885MAPT 4105/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HSPB1 89/4885FFAR4 3784/4885MAPT 4105/4885 |
| US-20130267534-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HSPB1 89/4885FFAR4 3784/4885MAPT 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.